1. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo-controlled trial 
Chinedu Nwokoro, MBBChir, Hitesh Pandya, MD, Stephen Turner, MD, Prof Sandra Eldridge, PhD, Prof Christopher J Griffiths, MD, Tom Vulliamy, PhD, Prof David Price, MRCGP, Marek Sanak, PhD, John W Holloway, PhD, Rossa Brugha, BMBCh, Lee Koh, BSC, Iain Dickson, MRes, Clare Rutterford, MSc, Prof Jonathan Grigg, MD 
The Lancet Respiratory Medicine 
Volume 2, Issue 10, Pages (October 2014)
DOI: /S (14)
Copyright © 2014 Nwokoro et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
*Perceived inefficacy is on the side of patient. †Data for the primary outcome were obtained from children whose parents responded to at least one follow-up phone call.
The Lancet Respiratory Medicine 2014 2, DOI: ( /S (14) )
Copyright © 2014 Nwokoro et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Dot plot of urinary LTE4 by variable numbers of copies of the Sp1-binding motif (either 5/5, 5/x, or x/x, in which x does not equal 5) in the ALOX5 promoter region
11 datapoints were outside the axis and are not shown for convenience. Horizontal bars within plots represent mean. LTE4=leukotriene E4. ALOX5=arachidonate 5-lipoxygenase.
The Lancet Respiratory Medicine 2014 2, DOI: ( /S (14) )
Copyright © 2014 Nwokoro et al. Open Access article distributed under the terms of CC BY Terms and Conditions